Short Interest in Haleon PLC Sponsored ADR (NYSE:HLN) Drops By 35.9%

Haleon PLC Sponsored ADR (NYSE:HLN) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 12,355,479 shares, a decline of 35.9% from the March 31st total of 19,282,381 shares. Based on an average daily volume of 6,562,399 shares, the short-interest ratio is currently 1.9 days. Currently, 0.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Haleon

A number of hedge funds have recently modified their holdings of the company. IHT Wealth Management LLC boosted its position in shares of Haleon by 6.9% in the fourth quarter. IHT Wealth Management LLC now owns 16,205 shares of the company’s stock worth $164,000 after purchasing an additional 1,049 shares during the period. National Bank of Canada FI boosted its position in shares of Haleon by 6.7% in the third quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock worth $156,000 after purchasing an additional 1,099 shares during the period. Oppenheimer & Co. Inc. boosted its position in shares of Haleon by 4.7% in the fourth quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock worth $250,000 after purchasing an additional 1,100 shares during the period. Cary Street Partners Financial LLC boosted its position in shares of Haleon by 20.1% in the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock worth $69,000 after purchasing an additional 1,113 shares during the period. Finally, Cardinal Capital Management boosted its position in shares of Haleon by 2.4% in the third quarter. Cardinal Capital Management now owns 48,085 shares of the company’s stock worth $431,000 after purchasing an additional 1,116 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Finally, HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Haleon presently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Performance

HLN stock traded down $0.05 during midday trading on Thursday, reaching $9.26. 8,797,556 shares of the company’s stock traded hands, compared to its average volume of 6,247,939. Haleon has a 52-week low of $8.71 and a 52-week high of $11.42. The stock has a market cap of $41.22 billion, a P/E ratio of 23.73, a PEG ratio of 1.97 and a beta of 0.26. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. The stock’s 50-day moving average is $10.05 and its 200 day moving average is $9.97.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The firm had revenue of $3.65 billion during the quarter. As a group, analysts anticipate that Haleon will post 0.56 EPS for the current year.

Haleon Announces Dividend

The company also recently declared a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be given a $0.1307 dividend. This represents a dividend yield of 266.0%. The ex-dividend date is Friday, April 10th. Haleon’s dividend payout ratio is presently 64.10%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.